Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts

Pacific Biosciences of California (PACB) stock rose 1.2% to $2.54, outperforming the S&P 500's 0.73% gain. Despite a 93.08% monthly surge, the company faces headwinds with projected EPS of -$0.13 (down 8.33% YoY) and revenue of $37.86 million (down 1.51% YoY). PACB holds a Zacks Rank of #4 (Sell) with unchanged consensus estimates over the past 30 days.